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arotid and Femoral Atherosclerosis
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OBJECTIVES The purpose of this work was to determine the predictive value of oxidized phospholipids
(OxPLs) present on apolipoprotein B-100 particles (apoB) in carotid and femoral athero-
sclerosis.
BACKGROUND The OxPLs are pro-inflammatory and pro-atherogenic and may be detected using the
antibody E06 (OxPL/apoB).
METHODS The Bruneck study is a prospective population-based survey of 40- to 79-year-old men
and women initiated in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)]
were measured in 765 of 826 (92.6%) and 671 of 684 (98.1%) subjects alive in 1995 and
2000, respectively, and correlated with ultrasound measures of carotid and femoral
atherosclerosis.
RESULTS The distribution of the OxPL/apoB levels was skewed to lower levels and nearly identical to
Lp(a) levels. The OxPL/apoB and Lp(a) levels were highly correlated (r  0.87, p  0.001),
and displayed long-term stability and lacked correlations with most cardiovascular risk factors
and lifestyle variables. The number of apolipoprotein (a) kringle IV-2 repeats was inversely
related to Lp(a) mass (r0.48, p 0.001) and OxPL/apoB levels (r0.46, p 0.001).
In multivariable analysis, OxPL/apoB levels were strongly and significantly associated with
the presence, extent, and development (1995 to 2000) of carotid and femoral atherosclerosis
and predicted the presence of symptomatic cardiovascular disease. Both OxPL/apoB and
Lp(a) levels showed similar associations with atherosclerosis severity and progression,
suggesting a common biological influence on atherogenesis.
CONCLUSIONS This study suggests that pro-inflammatory oxidized phospholipids, present primarily on
Lp(a), are significant predictors of the presence and extent of carotid and femoral
atherosclerosis, development of new lesions, and increased risk of cardiovascular events. The
OxPL biomarkers may provide valuable insights into diagnosing and monitoring cardiovas-
cular disease. (J Am Coll Cardiol 2006;47:2219–28) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.001Cardiology Foundation
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ehe pathogenesis of atherosclerosis involves a complex
nterplay of lipid abnormalities, oxidative stress, inflamma-
ion, and thrombogenicity that leads to clinical sequelae
1,2). Traditional risk factors, such as diabetes mellitus,
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Manuscript received September 8, 2005; revised manuscript received January 24,
006, accepted January 27, 2006.yperlipidemia, and hypertension are well accepted in con-
ributing to atherosclerosis. The significance of emerging
isk factors such as circulating oxidized low-density lipopro-
ein (OxLDL) is not as well established.
Plasma levels of oxidized phospholipids (OxPLs) present on
ndividual apolipoprotein B-100 particles (apoB), measured by
he murine monoclonal antibody E06 (3), have recently been
hown to be correlated with angiographic coronary artery
isease (CAD) (4), to be elevated after acute coronary syn-
romes (ACS) (5) and immediately after percutaneous coro-
ary intervention (PCI) (6). In addition, OxPL/apoB levels
ave been shown to strongly correlate with lipoprotein (a)
Lp(a)] (3–7) and to be preferentially bound by Lp(a) com-
ared with other apoB-containing lipoproteins (8).
In this prospective study using the Bruneck population
9–11), we examine OxPL/apoB levels and their relation-
hip to traditional risk factors, Lp(a), and the presence,
xtent, and development of carotid and femoral atheroscle-
osis and symptomatic cardiovascular disease (CVD).
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tudy subjects. The Bruneck study is a prospective
opulation-based survey of the epidemiology and pathogen-
sis of atherosclerosis (10–14). The study population was
ecruited as a gender- and age-stratified random sample of
ll inhabitants of Bruneck (125 women and 125 men in the
fth to eighth decades each, n  1,000). At the 1990
aseline, 93.6% of recruited subjects participated, with data
ssessment completed in 919 subjects. During follow-up
1990 to the re-evaluations in 1995 and 2000), subgroups of
3 and 97 individuals, respectively, died or moved away.
mong survivors, ultrasonographic follow-up of the carotid
nd femoral arteries was 96.5% (1995, n  826) and 93.8%
2000, n 684) complete. The current study focuses on the
995 examination and the follow-up period between 1995
nd 2000. Plasma samples for assessment of OxPL/apoB
ere available in 765 of the 826 subjects in 1995 (92.6%)
nd 671 of the 684 subjects in 2000 (98.1%). The study
rotocol was approved by the appropriate ethics commit-
ees, and all study subjects gave their written informed
onsent before entering the study.
linical examination and laboratory methods. All par-
icipants underwent a clinical examination and completed
tandardized questionnaires on current and past exposure
o vascular risk factors as described previously (10 –14).
lood samples were taken from the antecubital vein after
ubjects had fasted and abstained from smoking for
12 h. Low-density lipoprotein cholesterol was calcu-
ated with the Friedewald equation and corrected for the
ontribution of Lp(a) cholesterol, which was determined
y multiplying Lp(a) mass by 0.45 (14). Lipoprotein (a)
ass was measured by a double-antibody enzyme-linked
mmunoadsorbent assay (ELISA) using a polyclonal an-
iapolipoprotein (a) antibody for capture and monovalent
ntiapolipoprotein (a) Fab fragment coupled with perox-
dase for detection (interassay coefficients for variation
.5% to 6.3%) and apolipoprotein (a) phenotypes, mea-
ured as the number of kringle IV-2 repeats, as previously
Abbreviations and Acronyms
ACS  acute coronary syndromes
apoB  apolipoprotein B-100 particles
CAD  coronary artery disease
CCA  common carotid artery
CVD  cardiovascular disease
ELISA  enzyme-linked immunoadsorbent assay
ICA  internal carotid artery
Lp(a)  lipoprotein (a)
OxLDL  oxidized low-density lipoprotein
OxPL  oxidized phospholipid
PC  phosphorylcholine
PCI  percutaneous coronary intervention
POVPC  1-palmitoyl-2-(5-oxovaleroyl)-phosphocholineescribed (14). determination of OxPL/apoB levels with the OxLDL-
06 assay. The term OxLDL-E06 is used in a generic
ense to describe the assay. Chemiluminescent ELISA was
sed to measure OxPL/apoB levels, as previously described
3), using the murine monoclonal antibody E06, which
pecifically binds to the phosphorylcholine (PC) head group
f oxidized but not native phospholipids (15,16). Plasma
rom each sample was diluted 1:50 in phosphate-buffered
aline and 50 l added to microtiter wells coated with the
onoclonal antibody MB47 (5 g/ml), which specifically
inds apoB. Under these conditions, a saturating amount of
poB is added to each well, and, consequently, an equal
umber of apoB are captured in each well for all assays.
hus, the assay measurement of OxPL/apoB by design is
ndependent of apoB levels. The saturating concentration of
poB on the wells is approximately 1 to 2 g/ml, which
orresponds to plasma concentrations of 10 to 20 mg/dl,
elow all apoB concentrations of any patient in this cohort.
iotinylated E06 was then added to determine the amount
f OxPL present on each captured apoB (OxPL/apoB) and
he amount bound detected by a chemiluminescent technique,
xpressed as relative light units (RLUs) per 100 ms (3).
Before performing the OxPL/apoB measures, to confirm
hat a saturating amount of apoB was captured in each well,
validating assay was set up in parallel plates where MB47
5 g/ml) was plated to capture apoB similar as the
ethodology above. Then, biotinylated MB24, a murine
onoclonal antibody specific for a different epitope of apoB
5 g/ml), was added to quantitate the amount of apoB
aptured on the plates by MB47. In samples from the 1995
nd 2000 time points combined (n  1,436), the Spearman
ank correlation coefficient between OxPL measured on
ingle plates (expressed as RLU of E06 bound) and OxPL/
poB derived by using the parallel plates to measure apoB
nd calculating a ratio of E06 bound (E06 RLU) divided by
he amount of apoB bound (MB24 RLU) was r  0.995
p  0.001) (Fig. 1). Therefore, in this study, the OxPL/
poB value is presented as a ratio (rather than RLU)
etween E06 (OxPL) RLU divided by MB24 (apoB) RLU
easured in parallel plates. All samples for a given assay
ere run in a single assay, and internal controls consisting of
igh and low standard plasma samples were included to
etect potential variations between microtitration plates.
ach sample was assayed in triplicate. The intra-assay
oefficients for variation were 6% to 10%.
ssessment of atherosclerosis and CVD. The ultrasound
rotocol involves the scanning of the right and left common
arotid arteries (CCA), internal carotid arteries (ICA), and
emoral arteries with a 10-MHz imaging probe at the
ollowing locations: proximal CCA (15 to 30 mm proximal
o the carotid bulb), distal CCA (15 mm proximal to the
arotid bulb), and proximal ICA (carotid bulb, identified by
oss of the parallel wall present in the CCA and the initial
0 mm of the vessel above the flow divider between external
nd ICAs) and femoral artery (40 mm proximal and 10 mm
istal to the bifurcation into the superficial and deep
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June 6, 2006:2219–28 OxPLs and Atherosclerosisranches) (10,11,13). Atherosclerotic lesions were defined
ccording to two ultrasound criteria: 1) wall surface (pro-
rusion or roughness of the arterial boundary); and 2) wall
exture (echogenicity). The maximum axial diameter of
laques (in millimeters) was assessed on the near and far
alls at each of two (femoral arteries) and eight vessel
egments (carotid arteries). Femoral and carotid atheroscle-
osis scores were calculated by summing all diameters
carotid and femoral artery atherosclerosis score: intra-
bserver coefficients of variation, 13.5% and 14.0% [n 
00]) (17). The scores serve as measures of atherosclerosis
everity (ranges, 0 to 29.7 mm [carotid atherosclerosis score]
nd 0 to 13.6 mm [femoral atherosclerosis score]).
All scans were performed in 1995 and 2000 by the same
xperienced sonographer, who was unaware of the subjects’
haracteristics. Measurements were performed on-line. On
he basis of the follow-up evaluation, two different stages of
therosclerosis development/progression were differenti-
ted: 1) incident atherosclerosis was defined by the occur-
ence of atherosclerotic lesions in subjects initially free of
therosclerosis in given vascular beds (early atherogenesis);
nd 2) incident vessel stenosis was assumed whenever the
elative increase in the maximum plaque diameter exceeded
he double measurement error of the method and a narrow-
ng of the lumen 40% (diameter stenosis) occurred (ad-
anced atherogenesis) (10–13). The two progression cate-
ories were highly reproducible (kappa coefficients 0.8
n  100]). Further details of imaging procedures and
easurement errors have been published elsewhere (11,12).
Assessment of CVD was based on the patient’s medical
istory, a detailed review of the Bruneck Hospital databases,
nd the results of clinical and various laboratory examina-
ions (12,18). Myocardial infarction was deemed confirmed
igure 1. Plot of oxidized phospholipids (OxPL) values (in relative light
nits [RLU]) against OxPL/apolipoprotein B-100 particles (apoB) (ratio)
alues indicating a very high correlation of r  0.995, p  0.001
n  1,436).hen World Health Organization criteria for definite dis- case status were met. Stroke and transient ischemic attack
ere classified according to the criteria of the National
urvey of Stroke. The diagnosis of symptomatic peripheral
rtery disease required a positive response to the Rose
uestionnaire (typical claudication), with the vascular nature
f complaints confirmed by standard diagnostic procedures
ankle-brachial pressure index or angiography), or an acute
eripheral artery occlusion requiring revascularization.
tatistics. All calculations were performed using the SPSS
1.5 (SPSS Inc., Chicago, Illinois) and BMDP software
ackages (Statistical Solutions, Saugus, Massachusetts).
ontinuous variables were presented as means  SD or
edians (interquartile range), and dichotomous variables as
ercentages. Spearman correlation coefficients were used to
stimate the association between OxPL/apoB and Lp(a),
nd the associations between these variables and various
opulation characteristics. In Table 1, a Bonferroni correc-
ion was performed to account for multiple comparisons. In
ll other analyses, a two-sided p  0.05 was considered
ignificant.
The associations of OxPL/apoB and Lp(a) with carotid
nd femoral artery atherosclerosis and with CVD were
ested by means of logistic and linear regression analysis
Table 2). Base models were adjusted for age and gender.
ultiple regression analyses were adjusted for fixed sets of
ovariates that were assessed in previous analyses of the
ascular risk profiles of the Bruneck study population (13).
lternative models built by a forward stepwise selection
rocedure (allowing for all variables in Table 1) yielded
dentical results (data not shown); OxPL/apoB and Lp(a)
ere treated as continuous variables and loge-transformed to
atisfy the assumption of normality and constant variance of
he residuals. For comparability purposes odds ratios (95%
onfidence interval) and regression coefficients (95% confi-
ence interval) were calculated for a 1-SD-U increase in
oge-transformed OxPL/apoB and Lp(a) (Table 2). In
eparate equations tertile groups of OxPL/apoB were mod-
lled as a set of indicator variables. To test for linear trend,
e used the median level in each tertile group of OxPL/
poB as a continuous variable.
ESULTS
emographics. Demographic, clinical, and laboratory
haracteristics of the 765 study subjects in 1995 are shown
n Table 1. There were no differences between the 765
ubjects with OxPL/apoB measurements and the 61 with-
ut (data not shown). All subjects are of Caucasian origin.
istribution of OxPL/apoB and Lp(a) levels. The dis-
ribution of OxPL/apoB levels (1995 dataset) was skewed
ith most subjects having low levels (Fig. 2A) and strikingly
imilar to that of Lp(a) (Fig. 2B). The range of OxPL/apoB
evels was 0.018 to 0.860, and mean and median levels were
.109 and 0.051. A very strong correlation was noted
etween OxPL/apoB and Lp(a) levels (Spearman rank
orrelation coefficient r  0.87, p  0.001) (Fig. 2C). This
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OxPLs and Atherosclerosis June 6, 2006:2219–28orrelation applied to men and women and all other
ubgroups. The OxPL/apoB levels in paired samples (n 
71) from 1995 and 2000 were highly correlated (Spearman
ank correlation coefficient r  0.78, p  0.001) (Fig. 3).
hese correlation coefficients were higher than for low-
ensity lipoprotein (r  0.62, p  0.001), even excluding
Table 1. Characteristics of the Study Subjects
Phospholipids/Apolipoprotein B-100 Particles
Variables
Mean
Median
o
Age (yrs) 57.7
Female gender (%) 49
Vascular risk factors
Hypertension (WHO) (%) 36
Systolic BP (mm Hg) 148.0
Diastolic BP (mm Hg) 86.9
Current smoking (%) 19
Smoking (cigarettes/day) 2.6
Diabetes (WHO) (%) 9
Fasting glucose (mg/dl) 102.4
Ferritin (g/l) 135.0
Microalbuminuria (g/l)* 9.0 (7
Uric acid (mg/dl) 4.7
Coagulation
Fibrinogen (mg/dl) 288.2
Antithrombin III (%) 99.3
Activated protein C ratio 3.2
Lipids and lipoproteins
Total cholesterol (mg/dl) 229.7
Triglycerides (mg/dl)* 111 (
HDL cholesterol (mg/dl) 58.9
LDL cholesterol (mg/dl) 145.1
LDL cholesterol corr (mg/dl)§ 135.9
Apolipoprotein A (mg/dl) 166.0
Apolipoprotein B (mg/dl) 115.7
Lipoprotein (a) (mg/dl)* 12.1 (4
Infection and inflammation
Alpha-antithrypsin (mg/dl) 198.4
C-reactive protein (mg/l) 2.8
Hsp65 antibody (titer) 3.4
Cytomegalovirus IgG (titer) 3.1
Chlamydia pneumoniae IgA (titer) 3.1
Helicobacter pylori IgG (titer) 3.6
Vitamins
Retinol (mol/l) 2.4
Alpha-tocopherol (mol/l) 24.8
Carotenoids (mol/l) 1.4
Nutrition, activity, and body composition
Sports index (Beacke score) 2.4
Energy intake (kcal) 2,830
Fat intake (g/day) 147.7
Alcohol (g/day) 23.9
Body mass index (kg/m2) 25.6
Waist-hip ratio (cm/cm) 0.9
*Median and interquartile range (IQR) is presented for ske
coefficients; ‡correlations are significant after accounting fo
§LDL cholesterol corrected for the contribution of Lp(a) cho
subjects only. For the computation of correlation coefficien
cholesterol to mmol/l, multiply by 0.02586. To convert value
statistically significant.
BP  blood pressure; HDL  high-density lipoprotein;
WHO  World Health Organization.ubjects on statin therapy (r  0.71, p  0.001), and iigh-density lipoprotein (r 0.75, p 0.001) in years 1995
ersus 2000. Similarly, a strong correlation was noted
etween Lp(a) levels assessed in 1990 and 1995 (r  0.83,
 0.001).
Although weak positive correlations of OxPL/apoB were
oted with fibrinogen and antithrombin III and weak
) and Their Correlation With Oxidized
Lipoprotein (a) Levels (n  765)
D,
R),*
Correlation With
OxPL/apoB
Correlation With
Lipoprotein (a)
r† p Value r† p Value
.2 0.003 0.929 0.009 0.807
— — — —
— — — —
.5 0.073 0.044 0.036 0.317
0.036 0.326 0.011 0.768
— —
0.025 0.490 0.031 0.387
— —
.0 0.014 0.705 0.007 0.857
5.4 0.061 0.090 0.046 0.208
.0) 0.030 0.414 0.043 0.230
0.072 0.048 0.012 0.738
.8 0.101 0.005 0.133 0.001
.5 0.111 0.003 0.132 0.001
0.076 0.036 0.097 0.007
.4 0.089 0.014 0.178 <0.001‡
59) 0.114 0.002 0.019 0.597
.4 0.075 0.038 0.030 0.413
.9 0.125 0.001 0.239 <0.001‡
.9 0.010 0.788 0.066 0.070
.6 0.025 0.489 0.002 0.956
.3 0.008 0.830 0.093 0.010
.8) 0.874 0.001‡ — —
.6 0.035 0.330 0.019 0.608
0.008 0.826 0.021 0.569
0.025 0.496 0.066 0.069
0.003 0.940 0.014 0.689
0.001 0.969 0.002 0.948
0.011 0.770 0.003 0.931
0.140 0.007 0.135 0.008
.6 0.145 0.006 0.157 0.002
0.022 0.466 0.071 0.162
0.034 0.351 0.049 0.177
4 0.052 0.153 0.043 0.140
.3 0.064 0.077 0.050 0.171
.1 0.107 0.003 0.103 0.004
0.065 0.038 0.031 0.390
0.035 0.329 0.002 0.953
ariables; †values presented are Spearman’s rank correlation
multiple comparisons performed (Bonferroni adjustment);
ol; vitamin measurements were available in a sample of 390
e vitamins/LDL ratio was applied. To convert values for
riglycerides to mmol/l, multiply by 0.01129. Bold values are
 heat shock protein 65; LDL  low-density lipoprotein;(1995
and
 S
(IQ
r %
 11
.5%
.3%
 20
 9.1
.9%
 6.2
.4%
 25
 15
.0–18
 1.3
 72
 11
 0.6
 42
81–1
 16
 37
 36
 27
 31
.7–36
 36
 7.1
 1.2
 1.6
 1.6
 1.4
 1.1
 10
 0.7
 0.9
 86
 48
 31
 3.8
 0.1
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June 6, 2006:2219–28 OxPLs and Atherosclerosisocopherol, alcohol consumption, and triglyceride concen-
rations, these were no longer significant when adjusting for
he multiple comparisons performed (Table 1). The signif-
cant association with low-density lipoprotein cholesterol
isappeared when the Lp(a) contribution to the low-density
ipoprotein cholesterol was adjusted for (Table 1). In a
ultivariate analysis Lp(a) and alcohol consumption were
ound to be independently significant determinants of loge-
ransformed OxPL/apoB levels whereas all other variables
ere not. In line, Lp(a) did not show significant correlations
ith most of the demographic, lifestyle, and vascular risk
actors.
elationship of OxPL/apoB to apolipoprotein (a) phe-
otypes. The number of kringle IV-2 repeats was signifi-
able 2. Association of OxPL/apoB and Lp(a) Level with Presen
therosclerosis, and with Cardiovascular Disease
Models
Odds Ratio/R
(95%
arotid arteries
Presence of atherosclerosis 1995 (420 of 765)
Age-/gender-adjusted model 1.21 (1.
Multivariate model† 1.30 (1.
Atherosclerosis score 1995‡
Age-/gender-adjusted model 0.13 (0.
Multivariate model† 0.17 (0.
Incident atherosclerosis 1995–2000 (71 of 328)§
Age-/gender-adjusted model 1.31 (0.
Multivariate model† 1.44 (1.
Incident stenosis 40% 1995–2000 (65 of 308)§
Age-/gender-adjusted model 1.32 (1.
Multivariate model† 1.45 (1.
emoral arteries
Presence of atherosclerosis 1995 (332 of 765)
Age-/gender-adjusted model 1.17 (1.
Multivariate model† 1.23 (1.
Atherosclerosis score 1995‡
Age-/gender-adjusted model 0.14 (0.
Multivariate model† 0.16 (0.
Incident atherosclerosis 1995–2000 (106 of 390)§
Age-/gender-adjusted model 1.29 (1.
Multivariate model† 1.34 (1.
Prevalent/incident stenosis 40% (39 of 246)§
Age-/gender-adjusted model 1.38 (1.
Multivariate model† 1.51 (1.
ardiovascular disease
Presence of vascular diseases 1995 (77 of 765)
Age-/gender-adjusted model 1.47 (1.
Multivariate model† 1.46 (1.
Odds ratios and regression coefficients (marked with ‡) were derived from logistic
xPL/apoB and lipoprotein (a) level. The model included either OxPL/apoB level (le
djusted for age, gender, presence or absence of hypertension, presence or absence
ipoprotein and low-density lipoprotein (LDL) cholesterol, loge-transformed level of
tenosis has been adjusted for age, gender, presence or absence of diabetes and impai
evel of LDL cholesterol, fibrinogen and antithrombin III, and factor V Leiden mutat
cores were calculated by summing up the maximum diameter of atherosclerotic plaqu
nalyses loge-transformed atherosclerosis scores were used; §incident (non-stenotic) a
esions in subjects initially free of atherosclerosis in given vascular beds. Incident steno
nd focuses on subjects with pre-existing atherosclerosis. In the model targeting femor
o ensure a sufficient number of outcome events; cardiovascular disease subsumes
schemic stroke, transient ischemic attacks, and symptomatic peripheral artery diseas
apoB  apolipoprotein B-100 particles; coeff.  coefficient; Lp(a)  lipoproteinantly and inversely related to Lp(a) mass (r  0.48, p  r.001) and, interestingly, similar to OxPL/apoB (r 
0.46, p  0.001). Highly significant correlations between
p(a) mass and OxPL/apoB existed for all apolipoprotein
soforms (Fig. 4) with the strength of this correlation being
owest for the largest phenotypes and highest with the
owest number of kringle IV-2 repeats (29 repeats r 
.66, 23 to 29 repeats r  0.88, and 22 repeats r  0.93,
 0.001 each). The smallest apolipoprotein (a) pheno-
ypes were associated with the highest Lp(a) levels, as has
een previously described (14,19). There was substantial
ariability of Lp(a) mass for each apolipoprotein (a) isoform.
xPL/apoB levels by age and gender. The OxPL/apoB
evels were remarkably stable over the 40-year age range in
he study population (Spearman rank correlation coefficient
everity, and Progression of Carotid and Femoral Artery
/apoB Lp(a)
ion Coeff. p
Value
Odds Ratio/Regression Coeff.
(95% CI)*
p
Value
45) 0.031 1.22 (1.02–1.46) 0.028
57) 0.006 1.28 (1.06–1.55) 0.012
23) 0.008 0.12 (0.02–0.22) 0.016
26) 0.001 0.14 (0.04–0.24) 0.004
76) 0.066 1.25 (0.94–1.67) 0.132
96) 0.020 1.33 (0.97–1.81) 0.074
70) 0.031 1.24 (0.93–1.65) 0.151
92) 0.011 1.42 (1.02–1.96) 0.036
38) 0.051 1.17 (0.99–1.38) 0.061
46) 0.018 1.20 (1.01–1.43) 0.044
25) 0.013 0.15 (0.03–0.26) 0.011
27) 0.003 0.15 (0.04–0.26) 0.006
62) 0.032 1.15 (0.91–1.46) 0.252
71) 0.018 1.25 (0.97–1.60) 0.085
87) 0.039 1.70 (1.17–2.47) 0.006
14) 0.022 1.88 (1.22–2.89) 0.004
85) 0.001 1.39 (1.08–1.80) 0.012
86) 0.002 1.35 (1.03–1.76) 0.029
near regression analyses and calculated for a 1-SD-U increase of loge-transformed
d columns) or lipoprotein (a) (right-hand columns); †multivariate analyses have been
pothyroidism, smoking status, level of alcohol consumption, level of high-density
y albumin, ferritin level, and white blood cell count. The model of incident carotid
ucose tolerance, level of alcohol consumption, number of cigarettes smoked per day,
alues given are regression coefficients (95% confidence interval [CI]). Atherosclerosis
ight (carotid arteries) and two (femoral arteries) well-defined vessel segments. In the
clerosis (early atherogenesis) was defined by the development of first atherosclerotic
0% (advanced atherogenesis) was defined by the development of vessel stenosis40%
y stenosis,40% prevalent (1995) and incident (1995–2000) stenosis were combined
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OxPLs and Atherosclerosis June 6, 2006:2219–28omen (geometric means, 0.068 vs. 0.070; p  0.64 for
ifference). There were no differences of OxPL/apoB levels in
ubjects with and without smoking history (0.067 vs. 0.071,
 0.36) or subjects with and without diabetes (0.058 vs.
.069, p  0.33). Interestingly, subjects on statins had higher
evels of OxPL/apoB in 1995 (n  25, 0.102 vs. 0.068, p 
.021) and in 2000 (n  60, 0.096 vs. 0.061, p  0.001),
s previously noted in response to atorvastatin (3) and
ravastatin (20).
elationship between OxPL/apoB and Lp(a) with ath-
rosclerosis and CVD. Loge-transformed OxPL/apoB
evels were significantly associated with the presence of
arotid and femoral atherosclerosis and the carotid and
emoral atherosclerosis scores. Moreover, loge-transformed
xPL/apoB emerged as a significant risk predictor for the
evelopment of carotid and femoral atherosclerosis between
995 and 2000 and for the manifestation of vessel stenosis
40% in the carotid arteries as well as the presence of
emoral artery stenosis (Table 2). Finally, the significant
elation extended to symptomatic CVD (Table 2). In 1995
igure 2. Comparative presentation of distributions of oxidized phospho
B) and plot of OxPL/apoB versus lipoprotein (a) (C) indicating a very h
igure 3. Plot of oxidized phospholipids (OxPL)/apolipoprotein B-100a
articles (apoB) values in 1995 against OxPL/apoB values in 2000 indicating
onsiderable consistency over time (r  0.78, p  0.001, n 671).here were 77 subjects who had experienced one or more of
he following vascular diseases: ischemic stroke and tran-
ient ischemic attack, n  33; myocardial infarction, n 
7; and symptomatic peripheral artery disease n  31. The
umber of cases with incident CVD (1995 to 2000) was too
ow for a meaningful analysis. All associations for OxPL/
poB were independent of other cardiovascular risk factors,
xcept Lp(a), and applied equally to men and women. The
trength of association tended to decline with advancing age
nd to enhance with increasing low-density lipoprotein levels.
either of these trends, however, achieved significance.
Existence of significant associations between Lp(a) and
arotid atherosclerosis prevalence (1990) and progression
1990 to 1995) in the Bruneck study has been shown
reviously (14,21). Corresponding data for the 1995 exam-
nation and the 1995 to 2000 follow-up period are depicted
n Table 2. Interestingly, the findings for Lp(a) are very
imilar to those obtained for OxPL/apoB.
Finally, we divided OxPL/apoB levels into tertile groups.
he highest tertile of OxPL/apoB was associated with a
igher odds ratio for the presence (in 1995) and develop-
ent (1995 to 2000) of carotid and femoral atherosclerosis
Fig. 5), compared with the lowest tertile. In addition, the
ighest tertile of OxPL/apoB levels predicted the presence
f symptomatic CVD in 1995.
ISCUSSION
his large population study representative of the general
ommunity demonstrates for the first time that OxPL/apoB
evels are a significant predictor of the presence, extent, and
evelopment/progression of carotid and femoral atheroscle-
osis and are associated with an increased risk of cardiovas-
ular events. The OxPL/apoB and Lp(a) levels are similarly
istributed demographically, display long-term stability in
evels, and lack correlations with demographic, major vas-
ular risk, and lifestyle variables.
ecognition of PC on OxPL by murine monoclonal
ntibody E06. It was initially shown that E06 bound to
xLDL (22) and specifically to oxidized 1-palmitoyl-2-
(OxPL)/apolipoprotein B-100 particles (apoB) (A) and lipoprotein (a)
rrelation (data from 1995; r  0.87, p  0.001, n  765).lipidsrachidonoyl-phosphatidylcholine and 1-palmitoyl-2-(5-
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June 6, 2006:2219–28 OxPLs and Atherosclerosisxovaleroyl)-phosphatidylcholine (POVPC) (15) but not to
ther phospholipids, such as oxidized phosphatidylserine or
hosphatidylethanolamine. Interestingly, E06 bound both
o the isolated oxidized protein and lipid moieties of
xLDL after solvent extraction of the lipid phase (15,23).
n competition experiments, Friedman et al. (16) showed
hat E06 binding to OxLDL was inhibited by diverse and
nrelated OxPL peptides, including PC-keyhole limpet
emocyanin, PC-bovine serum albumin, and PC-lysine as
ell as by non-peptide antigens, such as aldol condensation
roducts of OxPL not attached to any peptides and PC
lone. Saponification of isolated POVPC or OxLDL (to
emove the PC headgroup) showed that the E06 immuno-
eactivity was completely abolished, confirming the essential
ole of PC in antigen recognition. Furthermore, the E06
ntibody gene is identical in the variable sequence to T15
atural antibodies that provide optimal protection against
neumococcal infection in mice. T15 antibodies bind PC
resent on gram-positive bacterial cell membranes, bound
o teichoic or lipoteichoic acid and not present as OxPL
24). Thus, there is molecular mimicry between the PC of
xLDL and the PC of pathogen. These findings have
llowed us to postulate that during oxidation of phospho-
ipids, a conformational change occurs that “presents” the
C headgroup in an immunogenic manner, thus differen-
iating normal phospholipids from OxPL.
xPL/apoB and atherosclerosis. The fact that OxPL/
poB levels predicted the presence, extent, and develop-
ent/progression of carotid and femoral atherosclerosis and
igure 4. Three-dimensional plot of oxidized phospholipids (OxPL)/apoli
nd apolipoprotein (a) [Apo(a)] phenotypes expressed as the number of kr
taken as the antilog of the mean of loge-transformed OxPL/apoB values)ymptomatic CVD suggests that OxLDL markers may be sseful in risk stratification of CVD. The strong association
etween OxPL/apoB and Lp(a) and their similar relation-
hip to carotid and femoral disease suggests a common
iological influence on atherogenesis and supports the
ypothesis that the atherogenicity of Lp(a) may be mediated
y associated OxPL.
The OxPL are pro-inflammatory and are present on
xLDL, apoptotic cells, and various innate immune mech-
nisms have evolved to bind and potentially neutralize them,
uch as natural monoclonal IgM autoantibodies, C-reactive
rotein (25), and scavenger receptors CD36 (26) and
R-B1 (23). Monoclonal antibody E06 can inhibit the
ptake of OxLDL by macrophages, suggesting it might
etard foam cell formation. Indeed, immunization of low-
ensity lipoprotein receptor/ mice with Streptococcus
neumoniae resulted in increased titers of OxLDL-specific
mmunoglobulin-M E06/T15 autoantibodies and decreased
therosclerosis progression (27). Several studies have also
oted an inverse association between immunoglobulin-M
iters to OxLDL and various manifestations of CVD
5,28–30).
elationship of OxPL/apoB and Lp(a). This study ex-
ends our recent observations that a strong correlation exists
etween OxPL/apoB and Lp(a) in patients with ACS (5),
CI (6), stable CAD (4), and after statin therapy in ACS
atients (3). This strong correlation appears to be due to
nhanced binding and affinity of OxPL for Lp(a), a unique
roperty in humans (6,8), as opposed to non-human pri-
ates that also have Lp(a) (31). For example, in the PCI
tein B-100 particle (apoB) levels according to lipoprotein (a) [Lp(a)] mass
IV-type 2 repeats. The OxPL/apoB levels presented are geometric meanspoprotudy (6), we showed that immediately post-PCI there was
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OxPLs and Atherosclerosis June 6, 2006:2219–28sharp increase in plasma OxPL/apoB levels, which were
istributed 50% on Lp(a) and 50% on non-Lp(a) apoB.
owever, by 6 h post-PCI, the majority (85%) of OxPL
ere on Lp(a), suggesting transfer and selective binding of
xPL to Lp(a). We have also shown that kringle V of
polipoprotein (a) has the ability to covalently bind up to 2
ol of OxPL, which are recognized by E06 (8). In addition,
igure 5. Multivariate analysis showing the association of oxidized phospholi
rogression of carotid and femoral artery atherosclerosis and with cardiovascu
rst tertile group (reference category) and the third tertile group. The p valuesreliminary data from our laboratory have shown that 40% 1o 70% of OxPL are actually present in the lipid phase of
p(a) whereas the remaining OxPL are on apolipoprotein
a) (31). Furthermore, in vitro transfer studies demonstrate
hat OxPL derived from OxLDL are preferentially trans-
erred to Lp(a) compared with low-density lipoprotein (31).
The current data are also remarkable for the fact that
xPL/apoB levels were relatively constant between years
xPL)/apolipoprotein B-100 particle (apoB) tertile groups with presence and
ease. For adjustment see Table 2. *p  0.05 for the comparison between the
ted in the figures are the overall p values for the three tertiles (test for trend).pids (O
lar dis995 and 2000, more so than high-density lipoprotein
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June 6, 2006:2219–28 OxPLs and Atherosclerosisholesterol or low-density lipoprotein cholesterol. These
ata are consistent with other studies showing that Lp(a)
evels remain relatively unchanged over time (19), except
uring acute phase responses or plaque disruption (3,5,6). In
his study, OxPL/apoB levels were higher in patients taking
tatins, which is consistent with our previous data showing
ncreases in OxPL/apoB levels in patients with ACS treated
ith atorvastatin (3) and in children with familial hyper-
holesterolemia treated with pravastatin (20). This is also
onsistent with data showing increases in Lp(a) after treat-
ent with several different statins (3). We have hypothe-
ized that this may represent efflux of OxPL from the vessel
all and transient binding in the circulation by Lp(a),
otentially as a mechanism of early plaque stabilization.
uch an increase in the OxPL/apoB ratio in response to an
ntervention may be a surrogate of effective therapy. Indeed,
e recently observed a similar increase in OxPL/apoB ratio
n healthy women in response to low fat diets, a situation
here apoB levels did not change (7). Additional potential
echanisms of the increase in OxPL/apoB include, among
thers, preferential clearance of native apoB compared to
inimally-modified PC-containing apoB, or differential
learance of Lp(a) particles that contain most OxPL
pitopes measured by E06. The reasons for the increase in
p(a) in response to statins and low fat diets are not yet
etermined. Proof of these hypotheses awaits further exper-
mental studies.
he role of Lp(a) and OxPL/apoB in atherogenesis. Li-
oprotein (a) is composed of apolipoprotein (a) covalently
ound to apoB of low-density lipoprotein by one disulfide
ond and has been associated with angiographically deter-
ined and clinically manifested CAD (32). This association
ppears to be particularly true in high-risk, as opposed to
ow-risk, populations. Interestingly, this study shows for the
rst time that the association of OxPL/apoB and Lp(a) was
trongest in those subjects with the highest Lp(a) concen-
ration but smallest apo (a) isoforms, suggesting that OxPL/
poB levels may be related to the number of K-IV2 repeats.
revious data from the Bruneck study showed that subjects
ith low-molecular weight apo (a) phenotypes and high
p(a) levels had more rapid progression of established
arotid atherosclerosis compared with those with high-
olecular-weight phenotypes (14). Similarly, hemodialysis
atients who are known for their enhanced oxidative stress
how the most pronounced association with CAD if they
re carriers of small apo(a) isoforms (33). Our findings
uggest that low-molecular phenotypes may be more
therogenic, either due to larger number of particles, or
erhaps through enhanced content of OxPL per unit of
p(a) mass.
The strong association and binding of OxPL by Lp(a)
ay be part of an innate immune response to detoxify
ro-inflammatory OxPL, analogous to the actions of
-reactive protein and natural immunoglobulin-M OxLDL
utoantibodies (34). In support of this concept is the idea
hat Lp(a) is highly enriched in platelet-activating factorcetyl hydrolase (seven-fold higher than low-density lipopro-
ein) (35,36), an enzyme that degrades OxPL, and that Lp(a)
ppears to increase in plasma in a manner similar to acute
hase proteins. This concept implies that some minimal levels
f Lp(a) may be beneficial. However, chronically elevated levels
ay be detrimental due to the associated pro-inflammatory
xPL, among other pro-inflammatory and -thrombotic
roperties, particularly due to the enhanced binding of
p(a) to the vessel wall matrix.
xPL as potential biomarkers. Given the very strong
orrelation between OxPL/apoB levels and Lp(a) concen-
ration, both variables are exchangeable in the risk models
Table 2) and provide similar information. However, if the
ypothesis holds true that scavenging of OxPL is an
mportant physiological role of Lp(a) and OxPL primarily
ccounts for atherogenicity of Lp(a), direct assessment of
xPL should allow for a more precise estimate of risk than
ssessment of entire Lp(a) mass. Remarkably, in this study
he associations between OxPL/apoB and all clinical and
ltrasound end points were stronger than those assessed for
p(a). Analogous findings have been obtained in a recent
tudy, where we showed that in patients 60 years old
xPL/apoB levels were indeed independent predictors of
ngiographically determined CAD, with all the typical risk
actors in the model (4). Measurement of pro-inflammatory
xPL on apoB-100 particles in plasma may be a surrogate
hat links atherogenesis and inflammation. Therefore, fur-
her research is required in distinct clinical populations to
scertain whether OxPL/apoB will provide clinically rele-
ant information on cardiovascular risk. Whether these will
ead to clinical utility awaits determination. Our data
uggest the novel hypothesis that the enhanced content of
xPL helps to explain the increased risk of CVD associated
ith Lp(a). Further animal and human studies will be
equired to delineate these pathways and assess their patho-
hysiological and clinical relevance. Prospective studies
valuating the change in the OxPL/apoB ratio in interven-
ion studies with clinical outcomes are also needed to
etermine how these changes in OxPL/apoB and their
elationship to Lp(a) can be applied for clinical decision
aking.
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